WuXi Biologics ('WuXi Bio') (HK:2269), a global Contract Research, Development and Manufacturing Organization (CRDMO), announced on Thursday that it has received six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excellence Awards (ABEA).
WuXi Biologics was named the winner in the following six categories: Best Contract Development & Manufacturing Organization Award, Best Aseptic Fill-Finish & Packaging CMO of the Year, Bioprocessing Excellence in Asia, Bioprocessing Excellence in China, Bioprocessing Facility of the Year, and Excellence in Bioprocessing Automation & Digitalization.
Additionally, WuXi Bio's chief technology officer, executive vice president, Dr. Sherry Gu, was named CTO of the Year and Dr. Jeremy Guo, head of Global Drug Product Operations, senior vice president, received the award of Head of Fill-Finish & Formulation of the Year.
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
OncoHost receives BIG Innovation Award in Health category
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient
Karyopharm Therapeutics awards inducement grants to new employees